Business Wire

MERZ

31.1.2020 09:04:13 CET | Business Wire | Press release

Share
Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero® , Cellfina® and Radiesse® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:

  • Dr. Tatjana Pavicic – Dermatologist, Germany
  • Dr. Kate Goldie – Aesthetic Physician, United Kingdom
  • Prof. Yana Yutskovskaya – Dermatologist, Russia
  • Dr. Jani van Loghem – Aesthetic Physician, Netherlands

Oral Presentations

Independent presentations including data on the Merz Aesthetics portfolio:

What’s new in minimally invasive treatments

  • Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2

Body shaping and cellulite

  • Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
  • Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)1 . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2

Biostimulatory fillers

  • Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1

E-Poster Presentations

E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .

  • Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
  • Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

BOCOUTURE® Milestone

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .

Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KgaA.

About Merz

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

1 Merz supported Investigator Initiated Trials

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility24.3.2026 11:01:00 CET | Press release

New AI-powered offering closes the gap between investment data and investor reporting, bringing institutional-grade automation to complex Fund of Funds structures Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem. Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as L

Meeting Rising AI Expectations and Removing Friction Key to Meeting Needs of B2B Buyers Across Europe24.3.2026 11:00:00 CET | Press release

8 in 10 buyers use AI in payments, but strategic integration remains uneven and caution abounds in France and GermanyPay by invoice, a core European expectation, a major growth lever in 2026, but payment preferences vary by country and company size According to a new European study1 of 550 business buyers commissioned by TreviPay, the global B2B payments invoicing and payments network, friction in the B2B buying process in the form of slow onboarding and inconsistent invoicing along with rising expectations for AI-enabled processes are where businesses are experiencing threats to loyalty beyond price. “Across Europe and the UK, finance teams are navigating economic pressure, regulatory complexity and rising buyer expectations,” said Inez Berkhof-Hollander, TreviPay’s Vice President of EMEA. “Our research shows payment and invoicing experiences now play a decisive role in supplier selection.” Top Three European Market Expectations in 2026 1. More AI-driven purchasing options vary by cou

OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 10:00:00 CET | Press release

The partnership enables secure integration of vehicle data from six Volkswagen Group brands into OCTO’s platform, strengthening fleet data services across the European Union and supporting utilization, maintenance and geo-location use cases without additional hardware. OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity report

Wolters Kluwer-undersøgelse: Danske SMV'er er førende i Europa inden for AI-drevet omkostningsbesparelser24.3.2026 10:00:00 CET | Pressemeddelelse

Høj reguleringsparathed og pragmatisk teknologiimplementering hjælper virksomheder med at skabe afkast, selvom finansieringsbegrænsningerne vokser Wolters Kluwer Tax & Accounting har i dag offentliggjort sin første rapport Future Ready Businessder viser, at danske små og mellemstore virksomheder (SMV'er) er de mest tilfredse i Europa med AI-drevet omkostningsbesparelser. Blandt SMV'er, der bruger AI, siger 65 %, at det har overgået forventningerne til omkostningsreduktion, hvilket er det stærkeste resultat på tværs af alle EU-markeder, langt foran lande som Tyskland og Spanien. Undersøgelsens resultater tegner et kontrastfyldt billede af markedet, hvor danske SMV'er kombinerer høj reguleringsparathed og en stærk præference for strategisk outsourcing med et stigende pres fra stigende omkostninger og begrænset adgang til kredit. "AI i Danmark implementeres med et klart forretningsmæssigt formål, ikke som en teknologisk trend," siger Martin Tage, Country Manager, Wolters Kluwer Tax & Acco

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye